Currently it seems that a TB at diagnosis is mandatory in advanced NSCLC, since some biomarkers such as PD-L1 need to be performed only on tumor tissue sections using immunohistochemistry. The gene discussed is CD274; the disease is non-small cell lung carcinoma.